<DOC>
	<DOCNO>NCT01441557</DOCNO>
	<brief_summary>Main objective : Evaluate effectiveness administration 3,4-diaminopyridine ( FIRDAPSE ® ) severe botulinic poisoning measure effect electrophysiological respiratory parameter Secondary Objective : Study natural history electrophysiological respiratory parameter botulinic intoxication Primary endpoint : Clinical , electrophysiological respiratory administration 3,4-diaminopyridine . Study Design : Pilot study , prospective , interventional . Study population : Case series ( n = 8 patient ) suffer botulinic type A , respiratory failure , organ failure Experimental treatment : 3,4-diaminopyridine , FIRDAPSE ® ( BioMarin ) The dosage gradually increase accord predetermined scheme exceed 60 mg / day 20 mg / dose . Statistics : Intra-individual comparison physiological parameter measure administration 3,4-diaminopyridine . Electromyographic respiratory parameter measure patient . Then dose 10 mg 3,4-diaminopyridine administrate . If dose well tolerated provide relative improvement 10 % least one parameter study , dose maintain 10 mg 48 hour 3 time day increase 20 mg . The primary endpoint change amplitude muscle response evaluate subtraction amplitude T1.5 T0 .</brief_summary>
	<brief_title>Pilot Study Usefulness 3,4-diaminopyridine Treatment Botulism</brief_title>
	<detailed_description>Main objective : Evaluate effectiveness administration 3,4-diaminopyridine ( FIRDAPSE ® ) severe botulinic poisoning measure effect electrophysiological respiratory parameter Secondary Objective : Study natural history electrophysiological respiratory parameter botulinic intoxication Primary endpoint : Clinical , electrophysiological respiratory administration 3,4-diaminopyridine . Study Design : Pilot study , prospective , interventional . Study population : Case series ( n = 8 patient ) suffer botulinic type A , respiratory failure , organ failure Experimental treatment : 3,4-diaminopyridine , FIRDAPSE ® ( BioMarin ) The dosage gradually increase accord predetermined scheme exceed 60 mg / day 20 mg / dose . Statistics : Intra-individual comparison physiological parameter measure administration 3,4-diaminopyridine . Electromyographic respiratory parameter measure patient . Then dose 10 mg 3,4-diaminopyridine administrate . If dose well tolerated provide relative improvement 10 % least one parameter study , dose maintain 10 mg 48 hour 3 time day increase 20 mg . The primary endpoint change amplitude muscle response evaluate subtraction amplitude T1.5 T0 . Quantitative variable express mean ± standard deviation median ( minimum - maximum ) qualitative variable percentage . The null hypothesis ( evolution identical two dos ) reject favour alternative hypothesis ( evolution different ) use mixed model analysis variance threshold 5 % first kind adjust amplitude T0 , age , time patient admission first administration 3,4-diaminopyridine . The evolution latency respiratory parameter analyze mixed ANOVA without risk adjustment alpha . For secondary objective , evolution curve amplitude muscle response one hand respiratory function hand , build patient . The mean ( median ) amplitude respiratory function wean calculate confidence level 95 % ( range ) . The average time first 3,4-diaminopyridine administration withdrawal mechanical ventilation also calculate . For dose , average evolution amplitude calculate confidence level 95 % . Statistical analysis carry use SAS software version 9.2 .</detailed_description>
	<mesh_term>Botulism</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>botulism ventilation renal failure cardiac failure pregnancy age 18 hepatic failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>mechanical ventilation</keyword>
</DOC>